B-condition	0	13	Anthracycline
I-condition	13	14	-
I-condition	14	21	induced
I-condition	22	36	cardiotoxicity
O	37	47	prevention
O	48	52	with
B-intervention	53	64	angiotensin
I-intervention	64	65	-
I-intervention	65	75	converting
I-intervention	76	82	enzyme
I-intervention	83	92	inhibitor
I-intervention	93	101	ramipril
O	102	104	in
O	105	110	women
O	111	115	with
O	116	119	low
O	119	120	-
O	120	124	risk
O	125	131	breast
O	132	138	cancer
O	138	139	:
O	140	147	results
O	148	150	of
O	151	152	a
O	153	164	prospective
O	165	175	randomized
O	176	181	study
O	181	182	.

O	183	196	Anthracycline
O	196	197	‑
O	197	204	induced
O	205	219	cardiotoxicity
O	220	221	(
O	221	224	AIC
O	224	225	)
O	226	233	remains
O	234	237	the
O	238	242	main
O	243	247	long
O	247	248	‑
O	248	252	term
O	253	265	irreversible
O	266	270	side
O	271	277	effect
O	278	280	in
O	281	291	malignancy
O	292	301	survivors
O	301	302	.

O	303	317	Cardiotoxicity
O	318	328	prevention
O	329	331	is
O	332	335	one
O	336	338	of
O	339	342	the
O	343	347	most
O	348	358	reasonable
O	359	369	approaches
O	369	370	.

O	371	373	In
O	374	378	this
O	379	390	prospective
O	391	401	randomized
O	402	406	open
O	406	407	‑
O	407	412	label
O	413	418	study
O	418	419	,
O	420	422	we
O	423	428	aimed
O	429	431	to
O	432	438	verify
O	439	446	whether
O	447	455	ramipril
O	456	464	protects
O	465	469	from
O	470	475	early
O	475	476	‑
O	476	481	onset
O	482	485	AIC
O	486	488	in
O	489	494	women
O	495	499	with
O	500	506	breast
O	507	513	cancer
O	514	515	(
O	515	517	BC
O	517	518	)
O	518	519	.

O	520	522	We
O	523	531	analyzed
O	532	536	data
O	537	541	from
B-total-participants	542	544	96
O	545	550	women
O	551	552	(
O	552	558	median
O	559	562	age
O	562	563	,
B-age	564	566	47
I-age	567	572	years
O	572	573	)
B-eligibility	574	578	with
I-eligibility	579	581	BC
I-eligibility	582	587	after
I-eligibility	588	594	breast
I-eligibility	595	602	surgery
I-eligibility	602	603	,
I-eligibility	604	611	without
I-eligibility	612	623	significant
I-eligibility	624	638	cardiovascular
I-eligibility	639	647	diseases
I-eligibility	647	648	,
I-eligibility	649	652	who
I-eligibility	653	657	were
I-eligibility	658	666	eligible
I-eligibility	667	670	for
I-eligibility	671	679	adjuvant
I-eligibility	680	694	anthracyclines
O	694	695	.

O	696	700	They
O	701	705	were
O	706	716	randomized
O	717	719	to
O	720	721	a
O	722	730	ramipril
O	731	733	or
B-control	734	741	control
I-control	742	745	arm
O	745	746	.

O	747	761	Cardiotoxicity
O	762	765	was
O	766	775	estimated
O	776	780	with
O	781	787	repeat
O	788	804	echocardiography
O	805	808	and
O	809	823	themeasurement
O	824	826	of
O	827	835	troponin
O	836	837	I
O	838	841	and
O	842	843	N
O	843	844	‑
O	844	852	terminal
O	853	861	fragment
O	862	864	of
O	865	868	the
O	869	879	prohormone
O	880	885	brain
O	886	897	natriuretic
O	898	905	peptide
O	906	907	(
O	907	909	NT
O	909	910	‑
O	910	916	proBNP
O	916	917	)
O	918	924	levels
O	925	929	over
O	930	931	1
O	931	932	‑
O	932	936	year
O	937	943	follow
O	943	944	‑
O	944	946	up
O	946	947	.

O	948	961	Anthracycline
O	961	962	‑
O	962	969	induced
O	970	984	cardiotoxicity
O	985	988	was
O	989	996	defined
O	997	999	as
O	1000	1001	a
O	1002	1010	decrease
O	1011	1013	in
O	1014	1018	left
O	1019	1030	ventricular
O	1031	1039	ejection
O	1040	1048	fraction
O	1049	1050	(
O	1050	1054	LVEF
O	1054	1055	)
O	1055	1056	,
O	1057	1065	elevated
O	1066	1075	biomarker
O	1076	1082	levels
O	1082	1083	,
O	1084	1087	and
O	1087	1088	/
O	1088	1090	or
O	1091	1101	occurrence
O	1102	1104	of
O	1105	1110	heart
O	1111	1118	failure
O	1119	1120	(
O	1120	1122	HF
O	1122	1123	)
O	1124	1126	or
O	1127	1134	cardiac
O	1135	1140	death
O	1140	1141	.

O	1142	1143	A
O	1144	1152	decrease
O	1153	1155	in
B-outcome	1156	1160	LVEF
I-outcome	1161	1166	above
I-outcome	1167	1169	10
I-outcome	1169	1170	‑
I-outcome	1170	1177	percent
I-outcome	1178	1184	points
O	1185	1193	occurred
O	1194	1196	in
B-iv-bin-percent	1197	1198	6
I-iv-bin-percent	1198	1199	.
I-iv-bin-percent	1199	1200	3
I-iv-bin-percent	1200	1201	%
O	1202	1204	of
O	1205	1213	ramipril
O	1214	1222	patients
O	1223	1226	and
B-cv-bin-percent	1227	1229	18
I-cv-bin-percent	1229	1230	.
I-cv-bin-percent	1230	1231	5
I-cv-bin-percent	1231	1232	%
O	1233	1243	ofcontrols
O	1244	1245	(
O	1245	1246	P
O	1247	1248	=
O	1249	1250	0
O	1250	1251	.
O	1251	1253	15
O	1253	1254	)
O	1254	1255	.

O	1256	1258	No
O	1259	1264	cases
O	1265	1267	of
B-outcome	1268	1270	HF
O	1270	1271	,
B-outcome	1272	1279	cardiac
I-outcome	1280	1285	death
O	1285	1286	,
O	1287	1289	or
B-outcome	1290	1294	LVEF
O	1295	1302	decline
O	1303	1308	below
O	1309	1311	50
O	1311	1312	%
O	1313	1317	were
O	1318	1326	reported
O	1326	1327	.

O	1328	1331	The
B-outcome	1332	1342	percentage
I-outcome	1343	1345	of
I-outcome	1346	1354	patients
I-outcome	1355	1359	with
I-outcome	1360	1368	elevated
I-outcome	1369	1371	NT
I-outcome	1371	1372	‑
I-outcome	1372	1378	proBNP
I-outcome	1379	1385	levels
O	1386	1395	increased
O	1396	1400	with
O	1401	1405	time
O	1406	1408	in
O	1409	1417	controls
O	1418	1419	(
O	1419	1420	P
O	1421	1422	=
O	1423	1424	0
O	1424	1425	.
O	1425	1428	003
O	1428	1429	)
O	1430	1433	and
O	1434	1442	remained
O	1443	1452	unchanged
O	1453	1455	in
O	1456	1459	the
O	1460	1468	ramipril
O	1469	1472	arm
O	1472	1473	.

O	1474	1476	At
O	1477	1480	the
O	1481	1484	end
O	1485	1487	of
O	1488	1494	follow
O	1494	1495	‑
O	1495	1497	up
O	1497	1498	,
O	1499	1501	an
O	1502	1510	increase
O	1511	1513	in
B-outcome	1514	1516	NT
I-outcome	1516	1517	‑
I-outcome	1517	1523	proBNP
I-outcome	1524	1530	levels
O	1531	1534	was
O	1535	1539	more
O	1540	1546	common
O	1547	1550	and
O	1551	1558	decline
O	1559	1562	was
O	1563	1567	less
O	1568	1574	common
O	1575	1577	in
O	1578	1581	the
O	1582	1589	control
O	1590	1594	than
O	1595	1603	ramipril
O	1604	1607	arm
O	1608	1609	(
O	1609	1610	P
O	1611	1612	=
O	1613	1614	0
O	1614	1615	.
O	1615	1617	01
O	1617	1618	)
O	1618	1619	.

O	1620	1622	No
O	1623	1634	significant
O	1635	1646	differences
O	1647	1649	in
O	1650	1658	troponin
O	1659	1665	levels
O	1666	1670	were
O	1671	1676	found
O	1677	1684	between
O	1685	1688	the
O	1689	1694	study
O	1695	1699	arms
O	1699	1700	.

O	1701	1709	Ramipril
O	1710	1713	was
O	1714	1718	well
O	1719	1728	tolerated
O	1729	1731	in
O	1732	1744	normotensive
O	1745	1750	women
O	1750	1751	.

O	1752	1754	In
O	1755	1765	relatively
O	1766	1771	young
O	1772	1777	women
O	1778	1782	with
O	1783	1785	BC
O	1786	1793	without
O	1794	1801	serious
O	1802	1815	comorbidities
O	1815	1816	,
O	1817	1820	who
O	1821	1829	received
O	1830	1844	anthracyclines
O	1844	1845	,
O	1846	1847	1
O	1847	1848	‑
O	1848	1852	year
O	1853	1862	treatment
O	1863	1867	with
O	1868	1876	ramipril
O	1877	1883	exerts
O	1884	1895	potentially
O	1896	1906	protective
O	1907	1914	effects
O	1915	1917	on
O	1918	1932	cardiotoxicity
O	1933	1941	assessed
O	1942	1946	with
O	1947	1949	NT
O	1949	1950	‑
O	1950	1956	proBNP
O	1957	1963	levels
O	1963	1964	.
